On August 4, 2022 Mevion Medical Systems, the leading provider of compact proton therapy systems for use in radiation treatment for cancer patients, reported that the accelerator for the MEVION S250i Proton Therapy System was delivered on July 28, 2022, to Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology in Wuhan, China (Press release, Mevion Medical Systems, AUG 4, 2022, View Source [SID1234617602]). This milestone commences the system installation at Tongji Hospital’s proton therapy center, the first of its kind in Central China.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The system at Tongji Hospital features Mevion’s industry leading HYPERSCAN Pencil Beam Scanning (PBS) technology and Adaptive Aperture pMLC. This powerful duo provides faster and more precise targeted dose delivery to tumors thus, minimizing the damage to surrounding healthy tissue and organs at risk. The system also integrates a diagnostic quality CT imaging system and a surface tracking system for high precision patient positioning and intra-fraction motion management.

Founded in 1900, Tongji Hospital currently treats over 6 million patients annually. It has developed into one of the world’s largest and most powerful oncology medical teaching and research facilities, and the recently opened Optics Valley Tongji Children’s Hospital is located on the same campus as the new proton therapy center. In addition to the Mevion system, the new proton therapy center will also be equipped with a cutting-edge whole-body PET/CT imaging system. Tongji Hospital has also built a second proton vault, making it China’s first proton center applying the One Plus One multi-system installation approach. This approach gives cancer centers the flexibility to add a second system in the future to correspond to the growth of patient volume and clinical expertise. By doing a staged installation approach, financial burdens are significantly reduced at the start of the clinical proton therapy program, and the risk of technology obsolescence is mitigated greatly.

"Mevion is excited to start the system installation at world-class Tongji Hospital, and we look forward to a continued partnership that will give patients in Central China much-needed access to proton therapy," said Tina Yu, Ph.D., chief executive officer and president of Mevion. "We are proud of our technology that provides advanced cancer treatment to patients and allows hospitals to expand their proton therapy program at their own pace."

*Mevion is actively seeking regulatory approval from the National Medical Products Administration (NMPA) in China.

On August 4, 2022 Omeros Corporation (NASDAQ: OMER), reported that the company will issue its second quarter financial results for the period ended June 30, 2022, on Tuesday, August 9, 2022, after the market closes (Press release, Omeros, AUG 4, 2022, View Source [SID1234617600]). Omeros management will host a conference call and webcast that same day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results as well as recent developments and highlights.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Conference Call Details

To access the live conference call via phone, please dial (833) 634-2592 from the United States and Canada or (412) 902-4100 internationally and ask to be placed into the Omeros earnings call. Please dial in approximately 10 minutes prior to the start of the call. A telephone replay will be available for one week following the call and may be accessed by dialing (877) 344-7529 from the United States, (412) 317-0088 internationally, and (855) 669-9658 from Canada. The replay access code is 4990130.

For online access to the live or subsequently archived webcast of the conference call, go to Omeros’ website at View Source

On August 4, 2022 DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, reported that its second quarter 2022 financial results will be released after the markets close on Wednesday, August 10th (Press release, DiaMedica, AUG 4, 2022, View Source [SID1234617599]). DiaMedica will host a live conference call on Thursday, August 11th at 7:00 AM Central Time to provide a business update and discuss financial results.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Interested parties may access the conference call by dialing in or listening to the simultaneous webcast. Listeners should log on to the website or dial in 15 minutes prior to the call. The webcast will remain available for play back on our website, under investor relations – events and presentations, following the earnings call and for 12 months thereafter. A telephonic replay of the conference call will be available until August 18, 2022, by dialing (800) 770-2030 (US Toll Free) and entering the replay passcode: 4814247.

On August 4, 2022 Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, reported the pricing of an underwritten public offering of 20,000,000 shares of its common stock at a public offering price of $3.50 per share (Press release, Poseida Therapeutics, AUG 4, 2022, View Source [SID1234617598]). The gross proceeds to Poseida from the offering, before deducting underwriting discounts and commissions and other estimated offering expenses, are expected to be approximately $70.0 million. In addition, Poseida has granted the underwriters a 30-day option to purchase up to an additional 3,000,000 shares of its common stock. All of the shares to be sold in the offering are to be sold by Poseida. The offering is expected to close on or about August 8, 2022, subject to customary closing conditions.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Piper Sandler and William Blair & Company, L.L.C. are acting as joint book-running managers for the offering. Cantor Fitzgerald & Co. and BTIG, LLC are also acting as book-running managers for the offering.

The offering is being made pursuant to a shelf registration statement on Form S-3, including a base prospectus, previously filed and declared effective by the Securities and Exchange Commission (the "SEC"). The offering is being made only by means of a written prospectus and prospectus supplement that form a part of the registration statement. A copy of the final prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and will be available for free on the website of the SEC at www.sec.gov. Copies of the final prospectus supplement and accompanying prospectus relating to the offering may be obtained, when available, by contacting Piper Sandler, Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, by telephone at (800) 747-3924 or by email at [email protected]; or William Blair & Company, L.L.C., Attention: Prospectus Department, 150 North Riverside Plaza, Chicago, IL 60606, by telephone at (800) 621-0687 or by email at [email protected].

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

On August 4, 2022 aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase biology platform, reported that it will report second quarter 2022 financial results and provide a corporate update after the market close on Monday, August 15, 2022 (Press release, aTyr Pharma, AUG 4, 2022, https://investors.atyrpharma.com/news-releases/news-release-details/atyr-pharma-webcast-conference-call-reporting-second-quarter-1 [SID1234617597]). Management will host a conference call and webcast to review the results and provide an operational update.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Participants who wish to join the conference call by telephone must register at the above dial-in registration link in order to receive the dial-in number and a personalized PIN code that will be required to access the call. Participants may join the live webcast by accessing it at the above webcast registration link on the aTyr Events page. For more information or questions, please contact aTyr’s investor relations team at [email protected].